Target Name: LITAF
NCBI ID: G9516
Review Report on LITAF Target / Biomarker Content of Review Report on LITAF Target / Biomarker
LITAF
Other Name(s): MGC116698 | MGC116700 | LITAF variant 2 | tumor protein p53 inducible protein 7 | lipopolysaccharide induced TNF factor | Lipopolysaccharide induced TNF factor, transcript variant 2 | Small integral membrane protein of lysosome/late endosome | Lipopolysaccharide induced TNF factor, transcript variant 1 | TP53I7 | p53-induced gene 7 protein | MGC125276 | LITAF_HUMAN | lipopolysaccharide-induced TNF-alpha factor | CMT1C | SIMPLE | MGC125275 | MGC116701 | PIG7 | MGC125274 | LITAF variant 1 | Tumor protein p53 inducible protein 7 | Lipopolysaccharide-induced tumor necrosis factor-alpha factor | small integral membrane protein of lysosome/late endosome | FLJ38636 | LPS-induced TNF-alpha factor | Lipopolysaccharide-induced tumor necrosis factor-alpha factor (isoform 1) | p53-induced protein 7

LITAF: A Potential Drug Target and Biomarker

Introduction

Literature has long recognized the importance of the immune system in fighting off infections and diseases. The immune system is a complex network of mechanisms that involve various cell types and signaling pathways. One of the key components of the immune system is the mononuclear phagocyte system, also known as the macrophage system. These cells play a crucial role in detecting and eliminating foreign particles, including bacteria, viruses, and other pathogens. In this article, we discuss a potential drug target and biomarker called LITAF (MGC116698), which is a protein that is expressed in high levels in the macrophages of individuals with rheumatoid arthritis.

The Importance of the Macrophage System

Macrophages are a type of white blood cell that are found throughout the body. They are an essential component of the immune system, as they help to detect and eliminate pathogens from the body. When a pathogen enters the body, it is typically detected by macrophages , which phagocytose (engulf) the pathogen and then present it to the rest of the immune system for further action.

Macrophages are also involved in the production of antibodies, which are proteins that are specific for a particular pathogen and help to neutralize it. They also produce cytokines, which are signaling molecules that help to coordinate the immune response. In addition, macrophages are involved in the production of anti-inflammatory compounds, which help to reduce inflammation and swelling.

The Role of LITAF in Macrophages

LITAF (MGC116698) is a protein that is expressed in high levels in the macrophages of individuals with rheumatoid arthritis. It is a member of the CD11b gene family and is characterized by the presence of a string of 255 amino acid residues in its C-terminus . LITAF is involved in various cellular processes, including inflammation, immune response, and cytokine production.

Studies have shown that LITAF is involved in the recruitment of immune cells to sites of infection or injury. It is also involved in the production of pro-inflammatory cytokines, such as TNF-伪 and IL-12. These cytokines help to attract more Many immune cells to the site of infection or injury and are involved in the inflammatory response.

In addition to its role in inflammation, LITAF is also involved in the regulation of cellular processes that are important for immune function. It is involved in the production of antibodies, as well as the regulation of cellular processes that are involved in T cell development and function.

Potential Therapeutic Use

The therapeutic potential use of LITAF is due to its involvement in the immune system and its role in the production of pro-inflammatory cytokines. Because LITAF is involved in the production of these molecules, it is a potential target for therapeutic intervention.

One approach to targeting LITAF is to use small molecules that can inhibit its activity. These molecules can be designed to interact with specific LITAF protein domains, such as its Fc portion or its ability to produce pro-inflammatory cytokines. By inhibiting LITAF's activity, it is possible to reduce the production of pro-inflammatory cytokines and improve immune function.

Another approach to targeting LITAF is to use antibodies that are specific for LITAF. These antibodies can be used to neutralize LITAF and reduce its production of pro-inflammatory cytokines. By using antibodies to target LITAF, it is possible to improve immune function and reduce the risk of developing inflammatory diseases.

Conclusion

In conclusion, LITAF is a protein that is expressed in high levels in the macrophages of individuals with rheumatoid arthritis. It is involved in various cellular processes that are important for immune function, including the production of antibodies and the regulation of pro

Protein Name: Lipopolysaccharide Induced TNF Factor

Functions: Plays a role in endosomal protein trafficking and in targeting proteins for lysosomal degradation (PubMed:23166352). Plays a role in targeting endocytosed EGFR and ERGG3 for lysosomal degradation, and thereby helps down-regulate downstream signaling cascades (PubMed:23166352). Helps recruit the ESCRT complex components TSG101, HGS and STAM to cytoplasmic membranes (PubMed:23166352). Probably plays a role in regulating protein degradation via its interaction with NEDD4 (PubMed:15776429). May also contribute to the regulation of gene expression in the nucleus (PubMed:10200294, PubMed:15793005). Binds DNA (in vitro) and may play a synergistic role with STAT6 in the nucleus in regulating the expression of various cytokines (PubMed:15793005). May regulate the expression of numerous cytokines, such as TNF, CCL2, CCL5, CXCL1, IL1A and IL10 (PubMed:10200294, PubMed:15793005)

The "LITAF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LITAF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Liver Bile Transporters (LBAT) | LIX1 | LIX1-AS1 | LIX1L | LKAAEAR1 | LKB1-LIP1-SMAD4 complex | LL22NC03-63E9.3 | LLCFC1 | LLGL1 | LLGL2 | LLPH | LMAN1 | LMAN1L | LMAN2 | LMAN2L | LMBR1 | LMBR1L | LMBRD1 | LMBRD2 | LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331